| Literature DB >> 30803073 |
Di Wu1, Meng Qin2, Duo Xu1, Lan Wang3, Chaoyong Liu2, Jie Ren1, George Zhou1, Chen Chen1, Fengmei Yang4, Yanyan Li4, Yuan Zhao4, Ruyi Huang5, Sina Pourtaheri6, Chunsheng Kang7, Masakazu Kamata8,9, Irvin S Y Chen3,8, Zhanlong He4, Jing Wen3,8, Wei Chen10, Yunfeng Lu1.
Abstract
Central nervous system (CNS) diseases are the leading cause of morbidity and mortality; their treatment, however, remains constrained by the blood-brain barrier (BBB) that impedes the access of most therapeutics to the brain. A CNS delivery platform for protein therapeutics, which is achieved by encapsulating the proteins within nanocapsules that contain choline and acetylcholine analogues, is reported herein. Mediated by nicotinic acetylcholine receptors and choline transporters, such nanocapsules can effectively penetrate the BBB and deliver the therapeutics to the CNS, as demonstrated in mice and non-human primates. This universal platform, in general, enables the delivery of any protein therapeutics of interest to the brain, opening a new avenue for the treatment of CNS diseases.Entities:
Keywords: blood-brain barrier penetration; central nervous system delivery; nanocapsules; nanomedicine
Mesh：
Substances：
Year: 2019 PMID： 30803073 PMCID： PMC6701476 DOI： 10.1002/adma.201807557
Source DB: PubMed Journal: Adv Mater ISSN： 0935-9648 Impact factor: 30.849